Gain Therapeutics (GANX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GANX · Stock Price

USD 1.87-0.08 (-4.10%)

Market Cap: $78.1M

Historical price data

Market Cap: $78.1MFounded: 2017HQ: Lugano, Switzerland

Sector Ranking#280 in Small Molecule Drugs #31 in AI / Machine Learning

Overview

Gain Therapeutics is a clinical-stage biotech leveraging its proprietary Magellan™ platform to discover novel allosteric small molecule therapies for disorders with high unmet medical need. Founded in 2017, the company's lead program, GT-02287, is a best-in-class candidate for GBA-Parkinson's disease currently in Phase 1 clinical studies. Its strategy focuses on modulating protein function through stabilization, destabilization, or degradation, moving beyond simple inhibition to address the root cause of complex diseases.

Neurodegenerative DiseasesParkinson's Disease

Technology Platform

Magellan™ is a proprietary AI and physics-based drug discovery platform that identifies novel allosteric binding sites on disease-implicated proteins to develop small molecule therapies capable of stabilizing, destabilizing, or degrading target proteins.

Funding History

3

Total raised:$52.5M

Series B$40MFountain Healthcare PartnersMar 15, 2021

Series A$10MViva BioInnovatorJun 15, 2019

Seed$2.5MUndisclosedJun 15, 2017

Opportunities

The primary opportunity is establishing GT-02287 as a first disease-modifying therapy for GBA-Parkinson's disease, a clear unmet need.

Secondly, the Magellan™ platform has broad applicability to other neurodegenerative and protein-misfolding disorders, enabling pipeline expansion and high-value partnerships.

Risk Factors

Key risks include clinical failure of the lead asset, the need for substantial additional capital to fund development, and intense competition in both the Parkinson's disease therapeutic space and the AI drug discovery sector.

Competitive Landscape

Gain faces competition from other GCase-targeting therapies in Parkinson's and numerous AI-driven drug discovery platforms. Its differentiation lies in GT-02287's novel allosteric chaperone mechanism and Magellan's specialized focus on physics-based identification of cryptic allosteric sites.